Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0L3MP
|
|||
| Former ID |
DCL001054
|
|||
| Drug Name |
VRX496
|
|||
| Synonyms |
Nelfinavir; nelfinavir; 159989-64-7; Viracept; Nelfinavir [INN:BAN]; AG1343; UNII-HO3OGH5D7I; AG-1343; C32H45N3O4S; NELFINAVIR MESYLATE AG1343; Viracept (TN); HO3OGH5D7I; CHEBI:7496; AG 1343; NLF; 1UN; 2-[2-HYDROXY-3-(3-HYDROXY-2-METHYL-BENZOYLAMINO)-4-PHENYL SULFANYL-BUTYL]-DECAHYDRO-ISOQUINOLINE-3-CARBOXYLIC ACID TERT-BUTYLAMIDE; (3S-(2(2S*,3S*),3alpha,4abeta,8abeta))-N-(1,1-Dimethylethyl)decahydro-2-(2-hydroxy-3-((3-hydroxy-2-methylbenzoyl)amino)-4-(phenylthio)butyl)-3-isoquinolinecarboxamide; NFV; NFV; Nelfinavir Monomethane Sulfonate; AG1346; Nelfinavir (INN); Nelfinavir [BAN:INN]; AG1343 (*Mesylate salt*); Viracept (TM)(*Mesylate salt*); Met-SDF-1beta & Nelfinavir; Met-Stromal Cell-derived Factor-1beta (Human) & Nelfinavir; (3S,4aS,8aS)-N-tert-butyl-2-[(2R,3R)-2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-phenylsulfanylbutyl]-3,4,4a,5,6,7,8,8a-octahydro-1H-isoquinoline-3-carboxamide
Click to Show/Hide
|
|||
| Drug Type |
Antisense drug
|
|||
| Indication | Acquired immune deficiency syndrome [ICD-11: 1C62.3; ICD-9: 42] | Approved | [1] | |
| Coronavirus infection [ICD-11: 1D92; ICD-10: B34.2] | Approved | [2] | ||
| Therapeutic Class |
Antisense
|
|||
| Company |
VIRxSYS Corporation
|
|||
| PubChem Substance ID |
9466, 612304, 644085, 828673, 7885113, 7980103, 8030419, 8189156, 14862000, 14886478, 29211928, 29215104, 29215105, 43121051, 46392782, 46507719, 48426124, 48426125, 48426126, 48426127, 49665993, 49853861, 49986443, 50418709, 53789140, 56320472, 57315038, 85177038, 85177042, 85177050, 91148445, 92717921, 93166553, 93167161, 96024947, 103956869, 104234156, 104330207, 104829285, 124800166, 124889990, 126621876, 126653609, 126681687, 128993952, 131300718, 134337994, 135023001, 137001914, 137261511
|
|||
| SuperDrug ATC ID |
J05AE04
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Human immunodeficiency virus Envelope messenger RNA (HIV env mRNA) | Target Info | . | [3] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018409) | |||
| REF 2 | ClinicalTrials.gov (NCT00246610) Safety Of VIRACEPT 625mg Administered To HIV-Infected Women During Pregnancy. U.S. National Institutes of Health. | |||
| REF 3 | Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.